Fanttik Day: Celebrating our 4th Anniversary with discounts
HOUSTON, Texas, May 26, 2024 /PRNewswire/ -- Fanttik, the multiple-award-winning auto-accessories brand, is kicking off its largest extravaganza of the…
Snapmaker Celebrates 8th Anniversary with Play Well Makerathon, Artisan Premium, and More
SHENZHEN, China, May 26, 2024 /PRNewswire/ -- Snapmaker, a leading innovator in the 3-in-1 3D printer market, is thrilled to…
Greg Walter Named President of Charlotte Motor Speedway
Click here for a high-resolution photo to support this release. CONCORD, N.C., May 25, 2024 /PRNewswire/ -- Today, Greg Walter,…
Media Advisory – Prime Minister’s itinerary for Sunday, May 26, 2024
OTTAWA, ON, May 25, 2024 /CNW/ - Note: All times local National Capital Region, Canada No public events scheduled This…
NASA Launches Small Climate Satellite to Study Earth’s Poles
WASHINGTON, May 25, 2024 /PRNewswire/ -- The first of a pair of climate satellites designed to study heat emissions at…
Statement by the Prime Minister on Africa Day
OTTAWA, ON, May 25, 2024 /CNW/ - The Prime Minister, Justin Trudeau, today issued the following statement on Africa Day:…
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Teladoc Health
NEW YORK, May 25, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential…
Celebrate International Skin Pigmentation Day with Cyspera Boost™
GENEVA, May 25, 2024 /PRNewswire/ -- As we mark this special day dedicated to raising awareness about skin pigmentation issues, Scientis…
Operation Feed the Frontline: Honoring Those Serving At the Border
TOMBSTONE, Ariz., May 24, 2024 /PRNewswire/ -- VoteYourVision.org proudly supports The AFBC Veteran's Foundation mission "Operation Feed the Frontline," a heartfelt…
/R E M I N D E R — Media Advisory – Prime Minister’s itinerary for Saturday, May 25, 2024/
OTTAWA, ON, May 24, 2024 /CNW/ - Note: All times local Greater Halifax Area, Nova Scotia 10:00 a.m. …
HI-Bio Announces Positive Results from Phase 2 Study of Felzartamab for Late Antibody-Mediated Rejection in Kidney Transplant Recipients
82% (n=9/11) of patients on felzartamab experienced resolution of antibody-mediated rejection per Banff criteria on biopsy at 24 weeks versus…
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label…
↑